Equities research analysts predict that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will announce earnings per share (EPS) of ($2.58) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. The lowest EPS estimate is ($3.40) and the highest is ($1.75). Tonix Pharmaceuticals posted earnings per share of ($61.00) during the same quarter last year, which suggests a positive year-over-year growth rate of 95.8%. The firm is expected to issue its next earnings results on Monday, March 16th.
According to Zacks, analysts expect that Tonix Pharmaceuticals will report full-year earnings of ($20.79) per share for the current fiscal year, with EPS estimates ranging from ($24.48) to ($17.09). For the next year, analysts anticipate that the firm will report earnings of ($4.04) per share, with EPS estimates ranging from ($5.98) to ($2.10). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Tonix Pharmaceuticals.
Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Friday, November 8th. The company reported ($5.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.35) by ($1.34).
NASDAQ:TNXP opened at $0.86 on Friday. The business’s 50-day moving average price is $1.49 and its 200 day moving average price is $1.01. The firm has a market cap of $5.61 million, a P/E ratio of 0.00 and a beta of 1.03. Tonix Pharmaceuticals has a 52-week low of $0.88 and a 52-week high of $42.00. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 0.01.
A number of large investors have recently added to or reduced their stakes in TNXP. Vanguard Group Inc. acquired a new position in Tonix Pharmaceuticals during the second quarter worth about $117,000. Acadian Asset Management LLC grew its holdings in Tonix Pharmaceuticals by 620.0% during the second quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock worth $89,000 after acquiring an additional 56,516 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in Tonix Pharmaceuticals during the second quarter worth about $42,000. 35.56% of the stock is currently owned by hedge funds and other institutional investors.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Recommended Story: Average Daily Trade Volume – ADTV
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.